Kyongbo Pharmaceutical Co., Ltd. (214390)

Overview

Kyongbo Pharmaceutical Co., Ltd, originally founded in 1987 as Kyongbo Chemical Co., Ltd., underwent a name change in March 2002 to better reflect its focus on pharmaceuticals. With its headquarters in Asan-si, South Korea, Kyongbo Pharmaceutical stands as a prominent entity in the pharmaceutical industry both locally and internationally. The company specializes in the manufacture and sale of active pharmaceutical ingredients (APIs) and finished drugs. Its commitment to health and wellness is showcased through its extensive product offerings that range from prescription drugs and over-the-counter (OTC) medicines to medical devices. Furthermore, Kyongbo Pharmaceutical is actively involved in contract development and manufacturing (CDMO) business, along with rigorous research and development activities aimed at innovating within the cardiovascular, anti-cancer, anti-psychotic, anti-virus, and infectious disease domains.

Products and Services

• Active Pharmaceutical Ingredients (APIs)

Kyongbo Pharmaceutical produces a diverse array of APIs, including general, cephalosporins, and anti-cancer APIs. These ingredients are crucial for the development of effective and safe pharmaceutical products, underscoring the company's role in fostering advancements in healthcare treatments.

• Prescription Drugs

The company offers a wide range of prescription drugs that cater to various health needs. These include products in the categories of anesthetic, cardiovascular, digestive system treatments, and antibiotics. Kyongbo Pharmaceutical's commitment to addressing a spectrum of health concerns is evident in its comprehensive prescription drug portfolio.

• Over-The-Counter (OTC) Drugs

Aside from prescription medications, Kyongbo Pharmaceutical also provides a selection of OTC drugs. These products are designed for self-care and treating minor ailments, allowing consumers to manage their health conveniently.

• Medical Devices

The company's foray into medical devices includes the manufacturing and distribution of portable X-ray machines and ultrasonic diagnostic equipment. Additionally, it offers extracorporeal shockwave therapy devices and temperature control PROBES, showcasing its versatility and innovative capabilities in healthcare technologies.

• CDMO Business

Kyongbo Pharmaceutical engages in contract development and manufacturing, providing comprehensive services from the development of pharmaceutical formulations to the manufacturing of finished products. This aspect of the business allows it to collaborate with other entities in the pharmaceutical industry, fostering partnerships and expanding its market presence.

• Research and Development

Focused on the future of healthcare, Kyongbo Pharmaceutical is deeply invested in the research and development of new drugs. Current projects include advancements in cardiovascular medications like Clopidogrel, anticancer treatments such as Imatinib, anti-psychotic drugs including Donepezil, antiviral treatments like Entecavir for virus and infectious diseases, and Esomeprazole for acid-related disorders. These R&D efforts highlight the company's commitment to innovation and improving patient outcomes.